Aequus Announces Zimed PF Now Available in Canada
VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS,
OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are
thrilled to announce the launch of Zimed PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
"This marks a new growth phase for Aequus and the launch of a Preservative Free (PF) innovation that brings value to both physicians and patients in a large therapeutic eye category,” says Grant Larsen, Chief Commercial Officer for Aequus Pharmaceuticals Inc. Canada. “An exciting product innovation, launched in multiple countries around the world, this product will be available at pharmacies across Canada in the coming weeks.”
For more information, please visit www.ZimedPF.ca and join us in celebrating this milestone in glaucoma treatment.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing
specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus, founded in 2015, has successfully grown multiple products and brands in
strategic therapeutic areas including Ophthalmology, Optometry, Transplant and Rare Disease. Aequus plans to build on its Canadian commercial platform through the application of sales, marketing
and expert knowledge of the Canadian marketplace utilizing internal development, acquisition, or licenses with preferred strategic partners. For further information, please visit www.aequuspharma.ca.
Lesen Sie auch
About Glaucoma, Dry Eye and Zimed PF
Zimed PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Glaucoma and elevated intraocular pressure can cause
vision loss or blindness by damaging the optic nerve located at the back of the eye. Dry eye disease is often associated with glaucoma due to factors including age, environment, allergies, and
preservatives in eyedrops. Zimed PF is the first preservative-free, multi-dose bottle bimatoprost available in Canada. Zimed PF (bimatoprost 0.03%) received market authorization
from Health Canada in December 2022.